Regeneus makes a healthy debut

Regeneus shares rise 8 per cent on first trading day.

Shares in Regeneus Ltd., the cell-based regenerative company, has a market value of $49.6 million after the stock rose 8 per cent on its first day of trade.

The Sydney-based company, founded in August 2007 to develop and commercialise cell treatment for humans and animals, closed up 2 cents at 27 cents, after rising as high as 29 cents.

The loss-making company had sold 42 million shares, or about a quarter of total stock, at 25 cents a share through the IPO underwriters, boutique investment bank Peloton Capital and stockbrokers BBY Ltd. The company has a total of 183.9 million of stock outstanding, according to Bloomberg data.

Australia’s IPO market is picking up, say bankers and lawyers, after a a 26 per cent drop in issuance year on year, according to Bloomberg data. Thirteen companies are due to sell shares in an IPO by year-end, according to Bloomberg. To date this year, 25 companies have sold shares in an IPO while 29 announced plans to do so.

Regeneus has developed and commercialised an autologous, a process that uses a patient’s own cells, for the treatment of musculoskeletal conditions in humans, as well as a treatment for dogs and horses. 

In the six months to end 2012, the company had a $3.6 million loss.

InvestSMART FORUM: Come and meet the team

We're loading up the van and going on tour from April to June, with events on the NSW central & north coast, the QLD mid-north coast and in Perth, Adelaide, Melbourne, Sydney and Canberra. Come and meet the team and take home simple strategies that you can use to build an investment portfolio to weather any storm. Book your spot here.

Want access to our latest research and new buy ideas?

Start a free 15 day trial and gain access to our research, recommendations and market-beating model portfolios.

Sign up for free

Related Articles